Predicted to enable cytokine activity; erythropoietin receptor binding activity; and protein kinase activator activity. Involved in several processes, including positive regulation of ERK1 and ERK2 cascade; positive regulation of activated T cell proliferation; and response to dexamethasone. Located in cell body and extracellular space. Used to study retinal detachment and visual epilepsy. Biomarker of cholangiocarcinoma; eye disease (multiple); transient cerebral ischemia; and vascular dementia. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); diabetic angiopathy; familial erythrocytosis 5; ischemia (multiple); and neurodegenerative disease (multiple). Orthologous to human EPO (erythropoietin); PARTICIPATES IN erythropoietin signaling pathway; hypoxia inducible factor pathway; cytokine mediated signaling pathway; INTERACTS WITH (+)-pilocarpine; 1H-indole; 2-methoxy-17beta-estradiol.
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] more ...
indole inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], indole inhibits the reaction [cobaltous chloride results in increased expression of EPO protein]
2-Methoxyestradiol promotes the reaction [methylmercuric chloride results in decreased expression of EPO protein], 2-Methoxyestradiol promotes the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP], EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP]
protocatechuic acid inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein], protocatechuic acid inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer], Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
bisphenol A inhibits the reaction [Cobalt results in increased expression of EPO mRNA], bisphenol A inhibits the reaction [HIF1A protein results in increased expression of EPO mRNA]
Cadmium inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EPO promoter]], Cadmium inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO mRNA], Diethylstilbestrol inhibits the reaction [Cobalt results in increased expression of EPO protein]
[cobaltous chloride results in increased expression of and results in increased activity of HIF1A protein] which results in increased expression of EPO protein more ...
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA], Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ...
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Hydrogen Peroxide], Hydrogen Peroxide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Indican inhibits the reaction [cobaltous chloride results in increased expression of EPO mRNA], Indican inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Ketoconazole inhibits the reaction [CYP3A4 protein promotes the reaction [Oxygen deficiency results in increased expression of EPO mRNA]], Ketoconazole inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in increased abundance of Nitrites]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]] more ...
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO protein results in decreased susceptibility to Levodopa], 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EPO results in increased phosphorylation of GSK3B protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein], benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein]
Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] more ...
Deferoxamine inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein], tetramethylthiourea inhibits the reaction [Reactive Oxygen Species results in decreased expression of EPO protein]
resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with C5 protein] results in increased secretion of EPO protein], resveratrol analog inhibits the reaction [[Cytochalasin B co-treated with IL5 protein] results in increased secretion of EPO protein]
[peginterferon alfa-2b co-treated with Ribavirin] affects the expression of EPO protein, [Ribavirin co-treated with Interferons] results in increased expression of EPO protein
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein, [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein
EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7 more ...
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein], Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA]
zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of EPO protein], zinc chloride inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
